194 related articles for article (PubMed ID: 31920642)
1. Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.
Li K; Zhan W; Chen Y; Jha RK; Chen X
Front Pharmacol; 2019; 10():1436. PubMed ID: 31920642
[TBL] [Abstract][Full Text] [Related]
2. Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer.
Li K; Zhan W; Jia M; Zhao Y; Liu Y; Jha RK; Zhou L
Int J Med Sci; 2020; 17(3):390-402. PubMed ID: 32132874
[No Abstract] [Full Text] [Related]
3. Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy.
Li K; Liu H; Gao W; Chen M; Zeng Y; Liu J; Xu L; Wu D
Biomaterials; 2015 Jan; 39():131-44. PubMed ID: 25477180
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
5. The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells.
Mansour M; van Ginkel S; Dennis JC; Mason B; Elhussin I; Abbott K; Pondugula SR; Samuel T; Morrison E
J Cancer; 2018; 9(23):4536-4546. PubMed ID: 30519360
[No Abstract] [Full Text] [Related]
6. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
7. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
[TBL] [Abstract][Full Text] [Related]
8. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy.
Yousefnezhad M; Davaran S; Babazadeh M; Akbarzadeh A; Pazoki-Toroudi H
Bioimpacts; 2023; 13(3):241-253. PubMed ID: 37431480
[TBL] [Abstract][Full Text] [Related]
9. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
Wang Q; Zou C; Wang L; Gao X; Wu J; Tan S; Wu G
Acta Biomater; 2019 Aug; 94():469-481. PubMed ID: 31141733
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of Docetaxel and Disulfonate Tetraphenyl Chlorin in One Nanoparticle Produces Strong Synergism between Chemo- and Photodynamic Therapy in Drug-Sensitive and -Resistant Cancer Cells.
Gaio E; Conte C; Esposito D; Miotto G; Quaglia F; Moret F; Reddi E
Mol Pharm; 2018 Oct; 15(10):4599-4611. PubMed ID: 30148955
[TBL] [Abstract][Full Text] [Related]
15. Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy.
Jin X; Zou B; Luo L; Zhong C; Zhang P; Cheng H; Guo Y; Gou M
Int J Nanomedicine; 2016; 11():4545-4552. PubMed ID: 27660446
[TBL] [Abstract][Full Text] [Related]
16. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma.
Kumbham S; Paul M; Itoo A; Ghosh B; Biswas S
Int J Pharm; 2022 Feb; 614():121479. PubMed ID: 35041911
[TBL] [Abstract][Full Text] [Related]
17. Injectable and Self-Healing Thermosensitive Magnetic Hydrogel for Asynchronous Control Release of Doxorubicin and Docetaxel to Treat Triple-Negative Breast Cancer.
Xie W; Gao Q; Guo Z; Wang D; Gao F; Wang X; Wei Y; Zhao L
ACS Appl Mater Interfaces; 2017 Oct; 9(39):33660-33673. PubMed ID: 28901139
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
19. PVA reinforced gossypolone and doxorubicin π-π stacking nanoparticles towards tumor targeting and ultralow dose synergistic chemotherapy.
Liu Y; Li K; Wu Y; Ma J; Tang P; Liu Y; Wu D
Biomater Sci; 2019 Aug; 7(9):3662-3674. PubMed ID: 31179466
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells.
Purohit MP; Verma NK; Kar AK; Singh A; Ghosh D; Patnaik S
ACS Appl Mater Interfaces; 2017 Oct; 9(42):36493-36512. PubMed ID: 28945070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
